NYSE:CAH - Cardinal Health Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $60.56
  • Forecasted Upside: 15.90 %
  • Number of Analysts: 8
  • Breakdown:
  • 2 Sell Ratings
  • 4 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.85 (-1.60%)

This chart shows the closing price for CAH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cardinal Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CAH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CAH

Analyst Price Target is $60.56
▲ +15.90% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Cardinal Health in the last 3 months. The average price target is $60.56, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 15.90% upside from the last price of $52.25.

This chart shows the closing price for CAH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 8 polled investment analysts is to hold stock in Cardinal Health. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 6 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 6 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 3 buy ratings
  • 4 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 2 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 4 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/26/2022BarclaysDowngradeOverweight ➝ Equal Weight$70.00 ➝ $64.00Low
5/18/2022Evercore ISIUpgradeIn-Line ➝ Outperform$55.00 ➝ $68.00Medium
4/12/2022Morgan StanleyUpgradeEqual Weight ➝ Overweight$74.00Medium
2/4/2022Credit Suisse GroupLower Price TargetNeutral$60.00 ➝ $58.00Low
2/4/2022Robert W. BairdBoost Price Target$52.00 ➝ $57.00Low
1/11/2022BarclaysLower Price TargetOverweight$65.00 ➝ $63.00High
12/17/2021Morgan StanleyLower Price TargetEqual Weight$64.00 ➝ $54.00Medium
11/15/2021Credit Suisse GroupLower Price TargetNeutral$53.00 ➝ $50.00Low
11/12/2021Deutsche Bank AktiengesellschaftBoost Price TargetHold$51.00 ➝ $59.00High
11/10/2021MizuhoLower Price TargetNeutral$56.00 ➝ $53.00Medium
11/10/2021BarclaysLower Price TargetOverweight$68.00 ➝ $65.00Medium
8/6/2021Evercore ISIReiterated RatingHold$50.00Low
8/6/2021BarclaysLower Price TargetOverweight$71.00 ➝ $68.00Low
8/6/2021Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold$62.00 ➝ $51.00Low
8/5/2021CitigroupDowngradeBuy ➝ Underperform$69.00 ➝ $56.00High
8/5/2021Bank of AmericaDowngradeBuy ➝ Underperform$69.00 ➝ $56.00High
7/13/2021Deutsche Bank AktiengesellschaftSet Price TargetBuy$57.44Low
5/17/2021Robert W. BairdReiterated RatingOutperform ➝ Neutral$66.00 ➝ $64.00Low
5/10/2021Robert W. BairdDowngradeOutperform ➝ Neutral$66.00 ➝ $64.00Low
3/3/2021Morgan StanleyLower Price TargetEqual Weight$66.00 ➝ $64.00Low
1/8/2021Wolfe ResearchUpgradeUnderperform ➝ Peer PerformMedium
11/13/2020MizuhoBoost Price TargetNeutral$56.00 ➝ $59.00Low
11/9/2020Morgan StanleyBoost Price TargetEqual Weight$61.00 ➝ $66.00Low
11/6/2020Robert W. BairdBoost Price TargetOutperform$64.00 ➝ $70.00Low
11/6/2020Deutsche Bank AktiengesellschaftBoost Price TargetBuy$61.00 ➝ $65.00Low
11/2/2020BarclaysUpgradeEqual Weight ➝ Overweight$57.00High
9/25/2020Deutsche Bank AktiengesellschaftUpgradeHold ➝ Buy$66.00 ➝ $61.00High
8/10/2020UBS GroupLower Price TargetBuy$65.00 ➝ $64.00Low
8/7/2020Morgan StanleyBoost Price TargetEqual Weight$59.00 ➝ $61.00Low
7/21/2020Bank of AmericaBoost Price TargetBuy$61.00 ➝ $63.00Medium
7/20/2020GuggenheimUpgradeNeutral ➝ BuyHigh
6/15/2020Morgan StanleyBoost Price TargetEqual Weight$57.00 ➝ $59.00High
5/15/2020Bank of AmericaUpgradeBuyHigh
5/15/2020UBS GroupUpgradeNeutral ➝ Buy$48.00 ➝ $64.00High
5/12/2020MizuhoBoost Price TargetNeutral$50.00 ➝ $56.00Medium
5/12/2020Morgan StanleyBoost Price TargetEqual Weight$51.00 ➝ $57.00High
5/11/2020CfraLower Price TargetHold$61.00 ➝ $58.00Low
4/22/2020Credit Suisse GroupDowngradeHold$53.00Low
3/27/2020Morgan StanleyLower Price TargetEqual Weight$64.00 ➝ $51.00Low
3/20/2020Bank of AmericaUpgradeUnderperform ➝ Buy$57.00 ➝ $58.00High
2/12/2020Morgan StanleyUpgradeUnderweight ➝ Equal Weight$48.00 ➝ $64.00Low
2/7/2020MizuhoBoost Price TargetNeutral$52.00 ➝ $58.00Low
2/7/2020Robert W. BairdUpgradeNeutral ➝ Outperform$54.00 ➝ $68.00Low
2/6/2020CfraBoost Price TargetHold$56.00 ➝ $61.00High
1/19/2020BarclaysReiterated RatingHold$54.00Low
12/16/2019GuggenheimDowngradeBuy ➝ NeutralMedium
9/12/2019GuggenheimSet Price TargetBuy$55.00Low
9/12/2019Deutsche Bank AktiengesellschaftInitiated CoverageHold$50.00Low
9/6/2019Morgan StanleyLower Price TargetUnderweight$50.00 ➝ $41.00N/A
8/27/2019ArgusDowngradeBuy ➝ HoldHigh
8/20/2019GuggenheimUpgradeNeutral ➝ Buy$50.00 ➝ $52.00Medium
4/17/2019GuggenheimInitiated CoverageNeutral ➝ Neutral$51.00High
4/2/2019Wolfe ResearchInitiated CoverageUnderperformHigh
1/17/2019UBS GroupInitiated CoverageNeutral ➝ Neutral$51.00Low
12/3/2018Morgan StanleyBoost Price TargetUnderweight ➝ Underweight$40.00 ➝ $50.00Low
11/16/2018SVB LeerinkDowngradeOutperform ➝ Market Perform$55.00High
11/14/2018Jefferies Financial GroupReiterated RatingHold$61.00Low
11/9/2018Royal Bank of CanadaSet Price TargetHold$57.00Low
9/21/2018Royal Bank of CanadaSet Price TargetHold$60.00High
8/12/2018MizuhoReiterated RatingHold$53.00Low
8/7/2018Robert W. BairdLower Price TargetNeutral ➝ Neutral$51.00 ➝ $50.00Low
8/7/2018Royal Bank of CanadaReiterated RatingHold$56.00Medium
7/20/2018Robert W. BairdReiterated RatingHold$51.00Low
7/16/2018ArgusLower Price TargetBuy ➝ Buy$85.00 ➝ $75.00Low
7/3/2018Morgan StanleyLower Price TargetUnderweight ➝ Underweight$55.00 ➝ $40.00Medium
5/7/2018MizuhoSet Price TargetHold$61.00Low
5/5/2018SVB LeerinkSet Price TargetBuy$65.00Low
5/4/2018Royal Bank of CanadaSet Price TargetHold$62.00High
5/4/2018Jefferies Financial GroupSet Price TargetHold$55.00High
4/24/2018Royal Bank of CanadaSet Price TargetHold$81.00Medium
4/24/2018SVB LeerinkUpgradeMarket Perform ➝ Outperform$75.00Low
4/16/2018BarclaysLower Price TargetEqual Weight ➝ Equal Weight$74.00 ➝ $68.00Medium
4/2/2018ArgusUpgradeHold ➝ Buy$85.00High
3/8/2018BarclaysInitiated CoverageEqual Weight ➝ Equal Weight$74.00Low
2/27/2018Bank of AmericaInitiated CoverageUnderperform ➝ Underperform$69.00Low
2/9/2018Jefferies Financial GroupSet Price TargetHold$72.00Low
2/8/2018Royal Bank of CanadaSet Price TargetHold$83.00Low
1/24/2018MizuhoSet Price TargetHold$73.00Low
1/17/2018Robert W. BairdReiterated RatingHold$80.00Medium
1/4/2018Evercore ISIInitiated CoverageIn ➝ In-Line$67.00Medium
12/4/2017Deutsche Bank AktiengesellschaftInitiated CoverageHold$64.00High
11/20/2017Morgan StanleyDowngradeEqual Weight ➝ UnderweightN/A
11/15/2017ArgusDowngradeBuy ➝ HoldN/A
11/7/2017Jefferies Financial GroupLower Price TargetHold$77.00 ➝ $67.00N/A
10/24/2017MizuhoSet Price TargetHold$70.00N/A
10/12/2017Needham & Company LLCReiterated RatingHoldN/A
9/19/2017Royal Bank of CanadaInitiated CoverageSector Perform ➝ Sector Perform$72.00Low
9/17/2017Robert W. BairdReiterated RatingHold$73.00Low
9/10/2017Needham & Company LLCReiterated RatingHoldLow
8/29/2017Jefferies Financial GroupSet Price TargetHold$77.00Low
8/9/2017UBS GroupReiterated RatingNeutral$79.00 ➝ $76.00Medium
8/3/2017UBS GroupReiterated RatingNeutral$79.00 ➝ $76.00Low
8/3/2017CowenReiterated RatingMarket Perform$82.00 ➝ $77.00Low
8/3/2017Credit Suisse GroupLower Price TargetOutperform$87.00 ➝ $81.00Medium
7/27/2017Jefferies Financial GroupReiterated RatingHold$77.00Low
7/13/2017Credit Suisse GroupReiterated RatingOutperform$81.00 ➝ $87.00Low
(Data available from 7/6/2017 forward)

News Sentiment Rating

0.02 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 7 very positive mentions
  • 30 positive mentions
  • 6 negative mentions
  • 1 very negative mentions
  • 2 very positive mentions
  • 7 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
  • 6 very positive mentions
  • 18 positive mentions
  • 6 negative mentions
  • 2 very negative mentions
  • 3 very positive mentions
  • 29 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
  • 2 very positive mentions
  • 18 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
  • 4 very positive mentions
  • 17 positive mentions
  • 8 negative mentions
  • 4 very negative mentions
  • 4 very positive mentions
  • 30 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
  • 2 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 2 very negative mentions

Current Sentiment

  • 2 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
Cardinal Health logo
Cardinal Health, Inc. operates as an integrated healthcare services and products company in the United States, Canada, Europe, Asia, and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, physician offices, and patients in the home. The company operates in two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. The segment also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; repackages generic pharmaceuticals and over-the-counter healthcare products; and offers medication therapy management and patient outcomes services to hospitals, other healthcare providers, and payers, as well as provides pharmacy management services to hospitals. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products and devices that include exam and surgical gloves; needles, syringe and sharps disposals; compressions; incontinences; nutritional delivery products; wound care products; single-use surgical drapes, gowns, and apparels; fluid suction and collection systems; urology products; operating room supply products; and electrode product lines. The segment also distributes a range of national brand products, including medical, surgical, and laboratory products; provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers; and assembles and sells sterile, and non-sterile procedure kits. It has a collaboration agreement with Journey Biosciences, Inc. Cardinal Health, Inc. was founded in 1979 and is headquartered in Dublin, Ohio.
Read More

Today's Range

Now: $52.25
Low: $51.32
High: $52.91

50 Day Range

MA: $55.07
Low: $50.48
High: $60.49

52 Week Range

Now: $52.25
Low: $45.85
High: $64.53


1,703,532 shs

Average Volume

2,778,606 shs

Market Capitalization

$14.23 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Cardinal Health?

The following Wall Street sell-side analysts have issued research reports on Cardinal Health in the last twelve months: Bank of America Co., Barclays PLC, Citigroup Inc., Credit Suisse Group AG, Deutsche Bank Aktiengesellschaft, Evercore ISI, Mizuho, Morgan Stanley, Robert W. Baird, StockNews.com, and TheStreet.
View the latest analyst ratings for CAH.

What is the current price target for Cardinal Health?

0 Wall Street analysts have set twelve-month price targets for Cardinal Health in the last year. Their average twelve-month price target is $60.56, suggesting a possible upside of 15.9%.
View the latest price targets for CAH.

What is the current consensus analyst rating for Cardinal Health?

Cardinal Health currently has 2 sell ratings, 4 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in CAH, but not buy more shares or sell existing shares.
View the latest ratings for CAH.

What other companies compete with Cardinal Health?

How do I contact Cardinal Health's investor relations team?

Cardinal Health's physical mailing address is 7000 CARDINAL PLACE, DUBLIN OH, 43017. The company's listed phone number is (614) 757-5000 and its investor relations email address is [email protected] The official website for Cardinal Health is www.cardinalhealth.com. Learn More about contacing Cardinal Health investor relations.